Decreased levels of serum platelet-activating factor acetylhydrolase in patients with rheumatic diseases

Mediators of Inflammation

Volumn 6, Issue 3, 1997, Pages 241-242

  Vergne, P ^a   Praloran, V ^b   Treves, R ^a   Denizot, Y ^b  

^a DUPUYTREN UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY OF LIMOGES   (France)

Author keywords

Acetylhydrolase activity; Osteoarthritis; Rheumatoid arthritis

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; THROMBOCYTE ACTIVATING FACTOR;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; MALE; OSTEOARTHRITIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID LEVEL;

EID: 0030755373     PISSN: 09629351     EISSN: None     Source Type: Journal    
DOI: 10.1080/09629359791758     Document Type: Article

References (13)

1. Braquet P, Touqui L, Shen TY, Vargaftig BB. Perspective in platelet-activating factor research. Pharmacol Rev 1987; 39: 97-145.
2. Stafforini DM, Prescott SM, Zimmerman GA, McIntyre TM. Mammalian platelet-activating factor acetylhydrolases. Biochim Biophys Acta 1996; 1301: 161-173.
3. Hilliquin P, Menkes CJ, Laoussadi S, Benveniste J, Arnoux B. Presence of PAF-acether in rheumatic diseases. Ann Rheum Dis 1992; 51: 29-31.
4. Dulioust A, Hilliquin P, Menkes CJ, Benveniste J, Arnoux B. Paf-acether acetylhydrolase activity is increased in patients with rheumatic diseases. Scand J Rheumatol 1992; 21: 161-164.
5. Hilliquin P, Houbaba H, Aíssa J, Benveniste J, Menkes CJ. Correlations between PAF-acether and tumor necrosis factor in rheumatoid arthritis. Scand J Rheumatol 1995; 24: 169-173.
6. Miwa M, Miyake T, Yamanaka T, et al. Characterization of serum platelet-activating factor (PAF) acetylhydrolase. Correlation between deficiency of serum PAF acetylhydrolase and respiratory symptoms in asthmatic children. J Clin Invest 1988; 82: 1983-1991.
7. Nathan N, Denizot Y, Feiss P. Eicosanoid and cytokine levels in plasma of patients during mesenteric infarction. Med Inflamm 1997; 6: 75-77.
8. Pritchard PH, Chonn A, Yeung CCH. The degradation of platelet-activating factor in the plasma of a patient with familial high density lipoprotein deficiency (Tangier Disease). Blood 1985; 66: 1476-1478.
9. Satoh K, Imaizumi TA, Kawamura Y, Yoshida H, Takamatsu S, Mizono S. Activity of platelet-activating factor (PAF) acetylhydrolase in plasma from patients with ischemic cerebrovascular disease. Prostaglandins 1988; 35: 685-698.
10. Denizot Y, Dupuis F, Trimorean F, Praloran V. Decreased levels of platelet-activating factor in blood of patients with lymphoid and nonlymphoid hematologic malignancies. Blood 1995; 85: 2992-2993.
11. Nathan N, Denizot Y, Hue MC, et al. Elevated levels of PAF-acether in blood in patients with type 1 diabetes mellitus. Diabete Metab 1992; 18: 59-62.
12. Arend WP, Dayer JM. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 1990; 33: 305-315.
13. Bonavida H, Mencia-Huerta JM. Platelet-activating factor and the cytokine network in inflammatory processes. Clin Rev Allergy 1995; 12: 381-395.